| Name | Title | Contact Details |
|---|---|---|
Mark Levine |
General Counsel | Profile |
Mark Levine |
General Counsel and Corporate Secretary | Profile |
Nutramax Laboratories, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Nutramax Laboratories, Inc. is based in Edgewood, MD. You can find more information on Nutramax Laboratories, Inc. at www.nutramaxlabs.com
Med-X Global is an LLC formed in the State of New Jersey. We operate as international revenue cycle consultants, third-party medical claims administrators and payment collectors adjudicating emergency medical claims for highly accredited foreign hospitals. Med-X also serves the ancillary emergency provider community in the foreign marketplace to include air and ground ambulance entities as well as premier urgent care centers and physician administered emergency sites. The majority of Med-X`s hospital clients operate clinically sophisticated facilities accredited by the General Heath Council (CSG) while still others are accredited by the Joint Commission International (JCI) reflecting a standard of care that typically meets or even exceeds the U.S. benchmark for quality providers.
Saint Francis Health Services is a Morris, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
DMS Health Group is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, & Biotech sector.